Chemed (CHE) Q3 2026 Earnings Call Transcript

Chemed (CHE) reported Q3 2026 earnings with total revenue up 10.6% and adjusted EPS up 28.1% YoY. VITAS saw 12.2% revenue growth, while Roto Rooter grew 7.5%. Roto Rooter's margins declined due to higher marketing costs and fuel expenses, but acquisitions are expected to drive long-term growth. The company has $229M in cash flow from operations, enabling strategic acquisitions and share repurchases.

Original reporting
Published Oct 28, 2026, 5:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 5:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Chemed (CHE) Q3 2026 Earnings Call Transcript — source image
Decision brief

The 30-second read

$CHEBullishHigh
01

Why it matters

The strong revenue and EPS growth, combined with robust cash flow and resolved Medicare cap issues, provide a clear catalyst for stock appreciation.

02

Market read

Chemed's earnings beat and cash generation are likely to drive positive sentiment in the healthcare services sector.

03

What to watch

Potential future Medicare cap constraints and higher marketing spend may impact profitability.

Relevance 8/10Novelty 8/10Timing: after-hours today

Background

Chemed Corp (CHE) released its Q3 2026 earnings call transcript, detailing financial performance across its VITAS and Roto Rooter segments.

Company-level read

Ticker impact

$CHEBullishHigh confidence
Context

Chemed reported Q3 2026 revenue up 10.6% and adjusted diluted EPS up 28.1% versus the prior year, with strong cash flow and no Medicare cap limitation.

Expected impact

likely upward pressure as the market prices in better-than-expected earnings and cash flow

Evidence & confidence

Revenue and EPS growth exceed prior year, Medicare cap issues resolved, and cash flow exceeds $229M, indicating improved fundamentals.

Market effects

Highlights strength in healthcare services and home health sectors, potentially boosting peers.

U.S. market focus, especially healthcare service stocks.

Moderate, as Chemed's performance may influence global healthcare service investors.

Counterpoint

Margin pressure from low-margin franchise acquisitions could offset earnings upside.

Key entities

  • Chemed Corp

    U.S.-listed provider of home health and specialty services.

Related articles

$CHEMedAI 9/10

Chemed 3Q 2026: Revenue $690.9M, EPS $5.45— 10-Q Summary

Chemed reported Q3 2026 revenue of $690.9M, up 10.6% YoY, with net income rising 11.5% to $71.6M and EPS increasing 22.2% to $5.45. Growth in VITAS and Roto-Rooter segments drove results, while higher fuel costs pressured margins. The company acquired RotoCo and other franchises, expanding its territories.

$CHEMed

What Chemed (CHE) Said on Its Q3 Earnings Call

Chemed reported Q3 earnings, with Roto-Rooter revenue up 7.5% but EBITDA down 2.5% due to higher costs. Commercial revenue grew 9% to $59.9M, while residential rose 5.2% to $158.8M. The company acquired California franchises for $62.5M, expecting $30M-$35M in 2027 revenue but less than $4M in EBITDA. Chemed repurchased 125,000 shares for $66M. Management expects 2026 EPS to meet or slightly exceed guidance.

$CHEMed

Chemed outlines 12- to 18-month integration timeline for $62.5M California Roto-Rooter franchise buyback while expecting 2026 EPS at or slightly above prior high end (NYSE:CHE)

Chemed (CHE) announced a 12- to 18-month integration timeline for its $62.5M California Roto-Rooter franchise buyback. CEO Kevin McNamara reported VITAS revenue grew 12.2% year-over-year, driven by ADC growth and cost containment. The company expects 2026 EPS to be at or slightly above the prior high end.

$CHEHighAI 8/10

Why is Chemed stock surging today?

Chemed (CHE) stock rose 9.2% after Q3 earnings beat estimates, with adjusted EPS of $6.75 and revenue of $690.9M. VITAS hospice division showed strong growth. Jefferies upgraded the stock to Buy, raising its price target to $620. Bank of America also increased its target to $555. The stock hit a 52-week high.